EGFR/HDAC-IN-2

EGFR/HDAC-IN-2 (Compound 38) is dual-functional inhibitor of EGFR and HDAC3 with IC50s of 20.34 and 1.09 nM for CDK9 and HDAC3, respectively. EGFR/HDAC-IN-2 has superior anti-proliferative activity against cancer cells, inhibits cell migration and induces late-stage cell apoptosis. EGFR/HDAC-IN-2 significantly inhibits triple-negative breast cancer (TNBC) tumor growth in xenograft mouse models. EGFR/HDAC-IN-2 can be used for cancers like TNBC research[1].

Product Specifications

UNSPSC

12352101

Target

Apoptosis; EGFR; HDAC

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

O=C(NCC1=CC=CC(F)=C1)C2=CC=C(NC(C3=CC=CC=C3F)=O)C=C2F

Molecular Formula

C21H15F3N2O2

Molecular Weight

384.35

References & Citations

[1]Ge GH, et al. Discovery and structural-activity relationship of N-benzyl-2-fluorobenzamides as EGFR/HDAC3 dual-target inhibitors for the treatment of triple-negative breast cancer. Bioorg Med Chem Lett. 2025 Dec 1;128:130362.